Abstract |
The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.
|
Authors | Md Nurunnabi, Seung-Ah Lee, Vishnu Revuri, Yong Hwa Hwang, Sung Hun Kang, Minhyung Lee, Sungpil Cho, Kwang Jae Cho, Youngro Byun, You Han Bae, Dong Yun Lee, Yong-Kyu Lee |
Journal | Journal of controlled release : official journal of the Controlled Release Society
(J Control Release)
Vol. 268
Pg. 305-313
(Dec 28 2017)
ISSN: 1873-4995 [Electronic] Netherlands |
PMID | 28860072
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017. Published by Elsevier B.V. |
Chemical References |
- Taurocholic Acid
- Glucagon-Like Peptide 1
- Heparin
- DNA
|
Topics |
- Animals
- Cell Line
- DNA
(administration & dosage, chemistry)
- Diabetes Mellitus, Type 2
(therapy)
- Diet, High-Fat
- Female
- Gene Transfer Techniques
- Genetic Therapy
- Glucagon-Like Peptide 1
(genetics)
- Heparin
(administration & dosage, chemistry)
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Rats, Sprague-Dawley
- Rats, Zucker
- Taurocholic Acid
(administration & dosage, chemistry)
|